E-resources
Peer reviewed
Open access
-
Baerends, Eva A M; Reekie, Joanne; Andreasen, Signe R; Stærke, Nina B; Raben, Dorthe; Nielsen, Henrik; Petersen, Kristine T; Johansen, Isik S; Lindvig, Susan O; Madsen, Lone W; Wiese, Lothar; Iversen, Mette B; Benfield, Thomas; Iversen, Kasper K; Larsen, Fredrikke D; Andersen, Sidsel D; Juhl, Anna K; Dietz, Lisa L; Hvidt, Astrid K; Ostrowski, Sisse R; Krause, Tyra G; Østergaard, Lars; Søgaard, Ole S; Lundgren, Jens; Tolstrup, Martin
Clinical infectious diseases, 11/2023, Volume: 77, Issue: 11Journal Article
Abstract Background Continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outpaces monovalent vaccine cross-protection to new viral variants. Consequently, bivalent coronavirus disease 2019 (COVID-19) vaccines including Omicron antigens were developed. The contrasting immunogenicity of the bivalent vaccines and the impact of prior antigenic exposure on new immune imprinting remains to be clarified. Methods In the large prospective ENFORCE cohort, we quantified spike-specific antibodies to 5 Omicron variants (BA.1 to BA.5) before and after BA.1 or BA.4/5 bivalent booster vaccination to compare Omicron variant-specific antibody inductions. We evaluated the impact of previous infection and characterized the dominant antibody responses. Results Prior to the bivalent fourth vaccine, all participants (N = 1697) had high levels of Omicron-specific antibodies. Antibody levels were significantly higher in individuals with a previous polymerase chain reaction positive (PCR+) infection, particularly for BA.2-specific antibodies (geometric mean ratio GMR 6.79, 95% confidence interval CI 6.05–7.62). Antibody levels were further significantly boosted in all individuals by receiving either of the bivalent vaccines, but greater fold inductions to all Omicron variants were observed in individuals with no prior infection. The BA.1 bivalent vaccine generated a dominant response toward BA.1 (adjusted GMR 1.31, 95% CI 1.09–1.57) and BA.3 (1.32, 1.09–1.59) antigens in individuals with no prior infection, whereas the BA.4/5 bivalent vaccine generated a dominant response toward BA.2 (0.87, 0.76–0.98), BA.4 (0.85, 0.75–0.97), and BA.5 (0.87, 0.76–0.99) antigens in individuals with a prior infection. Conclusions Vaccination and previous infection leave a clear serological imprint that is focused on the variant-specific antigen. Importantly, both bivalent vaccines induce high levels of Omicron variant-specific antibodies, suggesting broad cross-protection of Omicron variants. Comparison of antibody responses following bivalent BA.1 and BA.4/5 vaccination and impact of previous infection. Prior antigenic exposure leaves a clear serological imprint. Both bivalent vaccines induce high levels of Omicron variant-specific antibodies, suggesting broad cross-protection of Omicron variants. Graphical Abstract Graphical Abstract https://www.tidbitapp.io/tidbits/omicron-variant-specific-serological-imprinting-following-ba-1-or-ba-4-5-bivalentvaccination-and-previous-sars-cov-2-infection-a-cohort-study/update
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.